Home › Cancer (all types) › Pennsylvania
Cancer (all types) clinical trials in Pennsylvania
100 studies for Cancer (all types) are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
- Philadelphia57 studies
- Pittsburgh42 studies
- York7 studies
- Allentown7 studies
- Harrisburg4 studies
- Hazleton3 studies
- Reading3 studies
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Alliance Cancer Specialists - Media, Media
- Guthrie Medical Group, Sayre
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Nov 13, 2026 · NCT05920356Childhood Cancer Predisposition Study (CCPS)
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
All ages · All sexes · Updated Nov 12, 2026 · NCT04511806RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Pennsylvania, Philadelphia
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Nov 10, 2026 · NCT07002034Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Saint Luke's Cancer Center - Allentown, Allentown
- Saint Luke's University Hospital-Bethlehem Campus, Bethlehem
- and 21 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06580314Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- Allegheny Health Network, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07195591Pan Tumor Rollover Study
- Lancaster General Health, Lancaster
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT03899155Facial Expression Awareness Training to Understand and Recognize Emotions
- Children's Hospital of Philadelphia, Philadelphia
Recruiting
Ages 6 to 13 · All sexes · Updated Nov 6, 2026 · NCT07923370Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Lehigh Valley Health Network, Allentown
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Allegheny General Hospital (AGH)-Allegheny Singer Research Institute, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06901531A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
- University of Pennsylvania, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06150157Distance-Based Exercise to Preserve Function and Prevent Disability
- UPMC Hillman Cancer Center at Butler Health System, Butler
- UPMC Hillman Cancer Center - Passavant - Cranberry, Cranberry Township
- IRMC Cancer Center, Indiana
- and 6 more
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Alliance Cancer Specialists, PC, Horsham
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
- UPMC Cancer Centers, Pittsburgh
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06311578Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia
- Thomas Jefferson University - Clinical Research Institute, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- and 1 more
RecruitingPhase 2/3
All ages · All sexes · Updated Nov 2, 2026 · NCT03435796Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06959706A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 4021), Philadelphia
RecruitingPhase 1/2
1 Month – 17 Years · All sexes · Updated Oct 30, 2026 · NCT07630974Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 1 to 26 · All sexes · Updated Oct 28, 2026 · NCT07680439Collection of Tissue Samples for Cancer Research
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingObservational study
2 Months · All sexes · Updated Oct 27, 2026 · NCT00900198Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 2 to 99 · All sexes · Updated Oct 21, 2026 · NCT05783323Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Hospital of the University of Pennsylvania Perelman Center for Advanced Medicine ( Site 0100), Philadelphia
- UPMC Hillman Cancer Center ( Site 0101), Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07405164Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06162221Galleri® in the Medicare Population.
- Geisinger Bloomsburg Hospital - Bloomsburg, Bloomsburg
- FCCC - East Norriton, East Norriton
- FCCC - Buckingham, Furlong
- and 7 more
RecruitingHealthy volunteers welcome
Ages 50 and older · All sexes · Updated Oct 19, 2026 · NCT05673018A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
- University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07725796A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05123482A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275407, Philadelphia
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT07023289FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- UPMC Hilman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT03328078A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 3021), Philadelphia
RecruitingPhase 1/2
1 Month – 17 Years · All sexes · Updated Oct 6, 2026 · NCT06941272Autoimmunity After Checkpoint Blockade
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT04119713Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning
- Allegheny General Hospital, Pittsburgh
RecruitingObservational study
Ages 20 to 89 · Women · Updated Sep 30, 2026 · NCT07023887A Pilot Study Assessing Myokines During an EXErcise Regimen After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- Allegheny General Hospital, Pittsburgh
Recruiting
Ages 20 to 89 · Women · Updated Sep 30, 2026 · NCT07698314A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07192471EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
- AHN Allegheny General Hospital, Pittsburgh
- AHN Allegheny General Hospital, Pittsburgh
Recruiting
Ages 20 to 89 · Women · Updated Sep 28, 2026 · NCT07704476A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07277270First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
- GSK Investigational Site, Philadelphia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07438782A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- St. Lukes University Hospital /ID# 280204, Bethlehem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07365241TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lehigh Valley Hospital - Cedar Crest, Allentown
- Lehigh Valley Hospital- Muhlenberg, Bethlehem
- Pocono Medical Center, East Stroudsburg
- and 2 more
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 22, 2026 · NCT02693535Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Allegheny Health Network, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- Geisinger Medical Center-Cancer Center Hazleton, Hazleton
- and 4 more
Recruiting
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT06756607A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Fox Chase Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT06634589From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.